Processing your request


please wait...

Case Page

 

Case Status:    DISMISSED    
On or around 10/19/2020 (Notice of voluntarily dismissal)

Filing Date: September 08, 2020

According to the Complaint, Momenta Pharmaceuticals, Inc.is a biotechnology company with a validated innovative scientific platform focused on discovering and developing novel therapeutics to treat rare, immunemediated diseases.

Plaintiff brings this action on behalf of the public shareholders of Momenta against the Company and members of the Company’s Board of Directors for violations of Sections 14(d)(4), 14(e) and 20(a) of the Securities Exchange Act of 1934, in connection with the proposed acquisition of the Company by affiliates of Johnson & Johnson.

On August 19, 2020, the Company announced that it had entered into an Agreement and Plan of Merger with J&J. Pursuant to the terms of the Merger Agreement, Vigor Sub, Inc. (“Merger Sub”), a wholly-owned subsidiary of J&J, will merge with Momenta, with Momenta continuing as the surviving corporation and a wholly-owned subsidiary of J&J. To that end, Merger Sub commenced a tender offer to acquire all of Momenta’s outstanding common stock. Each share of Momenta common share will be converted into the right to receive $52.50. The Tender Offer is set to expire on September 30, 2020.

On September 2, 2020, the Company filed an allegedly incomplete and materially misleading Recommendation Statement with the SEC in connection with the Proposed Transaction. The Complaint alleges that the Recommendation Statement omits material information concerning the Proposed Transaction.

This case was voluntarily dismissed on October 19, 2020.

COMPANY INFORMATION:

Sector: Healthcare
Industry: Biotechnology & Drugs
Headquarters: United States

SECURITIES INFORMATION:

Ticker Symbol: MNTA
Company Market: NASDAQ
Market Status: Public (Listed)

About the Company & Securities Data


"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.

In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
COURT: S.D. New York
DOCKET #: 20-CV-07313
JUDGE: Hon. Lewis J. Liman
DATE FILED: 09/08/2020
CLASS PERIOD START: 08/19/2020
CLASS PERIOD END: 09/08/2020
PLAINTIFF FIRMS NAMED IN COMPLAINT:
  1. Lifshitz & Miller
No Document Title Filing Date
—Reference Complaint Complaint Related Data is not available
—Related District Court Filings Data is not available